ALGN
T3Align Technology, Inc.
OverviewAlign Technology, Inc. (ALGN) designs and manufactures Invisalign clear aligners (80% of 2025 revenue) and iTero intraoral scanners and services (20% of 2025 re
Align Technology, Inc. (ALGN) designs and manufactures Invisalign clear aligners (80% of 2025 revenue) and iTero intraoral scanners and services (20% of 2025 revenue). Invisalign offers orthodontic solutions for all ages, while iTero scanners and Exocad software provide digital imaging and CAD/CAM services for dentists and orthodontists, enhancing treatment planning and patient care. They serve a global network of dental professionals and DSOs.
- What They Do (Plain English & Analogies)
- Align Technology is like a digital orthodontist's toolkit and factory. They make clear, custom-fit plastic trays (Invisalign) that gently shift teeth into place, offering an alternative to traditional braces. They also create advanced 3D scanners (iTero) that dentists and orthodontists use to take digital impressions of teeth, eliminating messy molds. On top of that, they provide sophisticated software (Exocad) that helps dental professionals design crowns, bridges, and other restorations, and plan orthodontic treatments. Essentially, they provide the technology and products for both straightening teeth invisibly and for other digital dental procedures, making the process more efficient and patient-friendly.
- Very Brief History
- Align Technology, Inc. was founded in 1997 and is headquartered in Tempe, Arizona. The company pioneered the clear aligner market with its Invisalign system, launched in 1999. It expanded into digital dentistry solutions by introducing iTero intraoral scanners and later acquiring exocad CAD/CAM software, solidifying its leadership in digital orthodontics and restorative dentistry.
- "Street Stereotype"
- The "street stereotype" for Align Technology, as indicated by the "HaveNots Shorts '25: White Collar Services" theme, suggests that it is perceived as an elective dentistry company whose revenue can be sensitive to affluent consumer spending. There's a concern that macro uncertainty and cost-cutting could pressure volumes and pricing, leading to early-stage revenue pressure. Conversely, a recovery in discretionary corporate and affluent household spending could provide a sudden rebound.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Align Technology's customers are primarily in the dental and orthodontic sectors. Sectors include orthodontists, general practitioner (GP) dentists, Dental Service Organizations (DSOs), Orthodontic Service Organizations (OSOs), and dental labs. Example clients, based on transcript mentions of partnerships/relationships, include Heartland Dental and Spauld doctors (likely referring to a DSO like Spark Orthodontics or similar large networks).
- New Customers / Segments They'Re Targeting
- Align Technology is actively targeting several new customer sets and segments: teens and growing kids (early intervention) with products like Invisalign First and the Invisalign Palate Expander System; general practitioner (GP) dentists, aiming to accelerate their engagement in restorative dentistry by integrating iTero scanning and Exocad software; and Dental Service Organizations (DSOs) and Orthodontic Service Organizations (OSOs), which are crucial strategic growth channels for accelerating the adoption of their digital solutions. They are also offering more portfolio flexibility, including streamlined configurations with lower upfront cost options, to meet diverse patient needs and drive adoption.
- Supply Chain And Sourcing Geographies
- Align Technology operates a global supply chain. Clear aligners are manufactured in Juarez, Mexico; Ziyang, China; and Wroclaw, Poland (for the EMEA region). Scanners are manufactured in Israel and China. Treatment planning operations are located in Costa Rica; Wroclaw, Poland; Madrid, Spain; Cologne, Germany; and France. The company's headquarters and support functions are in Tempe, Arizona, U.S. The company is also advancing direct fabrication, transitioning to 3D printing of clear aligner appliances and attachments.
- Sales Geographies And Expansion Plans
- Align Technology sells its products worldwide, with current sales geographies including the United States, Switzerland, China, EMEA (Europe, Middle East, and Africa, with specific strength in Iberia, The Nordics, and The UK), Latin America (where it surpassed one million patients treated), and APAC (Asia-Pacific, with record Q4 shipments by China, India, and Korea). The company plans to expand international adoption by tailoring regional specific strategies, supported by local manufacturing and product offerings, to unlock meaningful, untapped demand. They are also focused on strengthening North America and scaling internationally.
- How Key Themes May Help/Hurt
- The 'White Collar Services' theme suggests that Align Technology, as an elective dentistry provider, could be hurt by macroeconomic uncertainty, corporate cost-cutting, and softness in white-collar labor markets, leading to reduced discretionary spending on treatments like Invisalign. The transcript acknowledges a 'dynamic macro environment' and 'continued softness in North America retail chain where consumer sentiment and patient inflow remained pressured', aligning with this concern. Conversely, if the theme's 'Bear Points' materialize, such as a resumption of office rehiring or a sudden return of affluent household discretionary spending, Align Technology could see a rebound in demand.
3 Main Long-Term Bull Details
- Expanding International Adoption and Untapped Demand: Significant growth opportunities exist in international markets (EMEA, Latin America, APAC), where the company is tailoring regional strategies and product offerings to tap into substantial underpenetrated demand.
- Innovation in Digital Orthodontics and Direct Fabrication: Continued investment in AI-driven treatment planning (ClinCheck Y plan), integrated digital workflows, and the transition to direct fabrication (3D printing of aligners and attachments) promises improved predictability, increased speed, enhanced margins, and new design flexibility.
- Strategic Growth in Teen/Kids Segment and DSOs: The 'teens and growing kids' category, supported by unique solutions like Invisalign First and the Palate Expander System, represents a major long-term opportunity. Additionally, DSOs and OSOs are proving to be highly scalable and influential strategic growth channels, driving increased adoption and utilization of Align's digital platform.
3 Main Long-Term Bear Details
- Macroeconomic Headwinds and Consumer Discretionary Spending: The company acknowledges a 'dynamic macro environment' and 'continued softness in North America retail chain where consumer sentiment and patient inflow remained pressured'. As an elective procedure, Invisalign treatment can be sensitive to economic downturns and reduced consumer discretionary spending.
- Pricing Pressure and Competitive Landscape: While Align maintains a strong market position, it faces competition. The transcript mentions 'higher discounts' impacting ASPs and the potential for 'volume based procurement process or VPP' in China to lead to 'eventual pricing changes', indicating ongoing pricing pressures.
- Execution Challenges in North America and Conversion Rates: Despite overall growth, the company notes 'continued softness in North America' for teens and kids and emphasizes the need for 'strengthening North America' and 'improving conversion throughout the funnel'. Consistent execution across regions and channels, particularly in challenging markets, remains a critical factor.
- Competitors And Differentiation
- Align Technology faces competition in both clear aligners and intraoral scanners. Clear aligner competitors include Angelalign, Straumann Group, Envista (Spark Aligners), 3M (Clarity Aligners), Dentsply Sirona (SureSmile), Candid Co., Shanghai Smartee Denti-Technology Co., Ltd., Graphy Inc., Formlabs Inc., TP Orthodontics Inc., and Scheu-Dental GmbH. (Note: SmileDirectClub, previously a competitor, filed for bankruptcy in late 2023). Intraoral scanner competitors include Dentsply Sirona (Primescan), 3Shape (Trios), and 3M (True Definition Scanner). Align differentiates itself through its integrated digital ecosystem (Invisalign, iTero, Exocad), advanced AI-driven treatment planning (ClinCheck Y plan), global manufacturing scale, continuous innovation (direct fabrication, Align Oral Health Suite, Align X-ray Insights), broad clinical applicability, and strong brand preference.
- Recent Performance & What The Market'S Focused On
- Align Technology reported a strong finish to 2025, with record Q4 revenues of $1.048 billion (up 5.3% year over year) and full-year 2025 revenues of $4 billion (up 1% year over year). Clear aligner volumes were also a record, up 7.7% year over year in Q4. Non-GAAP operating margin reached 26.1% in Q4, the highest since 2021. The market is focused on sustaining growth and stability, particularly in North America; the continued strong performance of DSOs and international markets; the timeline and margin impact of the direct fabrication rollout; the eventual timing and scope of China's VBP implementation; and the company's outlook for 100 basis points of non-GAAP operating margin improvement in 2026.
- Revenue Segments And Estimated Mix
- Clear Aligner — Mix: ~79.5% (Q4 2025); Source: Q4 2025 transcript; Trend: Q4 revenues up 5.5% year over year; FY25 revenues up 0.5% year over year. Volume up 7.7% year over year in Q4, 4.7% for FY25.
- Systems and Services (iTero solutions and Exocad software) — Mix: ~20.5% (Q4 2025); Source: Q4 2025 transcript; Trend: Q4 revenues up 4.2% year over year; FY25 revenues up 2.7% year over year.
- Product Brands
- Invisalign
- iTero
- Exocad
- Invisalign First
- Invisalign Palate Expander System
- MAOB (Mandibular Advancement with Occlusal Blocks)
- iTero Lumina
- Exocad ART (Advanced Restorative Treatment)
- Align Oral Health Suite
- Align X-ray Insights (AXI)
- ClinCheck Y plan
- Invisalign Specifics
Bull / Bear DetailsAlign Technology faces persistent headwinds from North American retail market softness and declining average selling prices, exacerbated by a dynamic macroecono
Thesis
Align Technology faces persistent headwinds from North American retail market softness and declining average selling prices, exacerbated by a dynamic macroeconomic environment impacting discretionary spending. While international expansion and DSO growth provide some offset, initial margin dilution from direct fabrication and ongoing competitive pressures suggest a challenging path to sustained profitability expansion. The bear case remains more compelling as of April 24, 2026.
Bull case
Align continues to demonstrate strong international growth, with double-digit clear aligner volume increases in EMEA, Latin America, and APAC, reaching significant patient milestones. Dental Service Organizations (DSOs) also remain a high-growth channel, representing approximately 25% of Align's business and driving significant adoption of Invisalign and iTero systems globally.
The company's robust product portfolio, including Invisalign First, the Palate Expander, and MAOB, is successfully driving growth in the teen and growing kids segment, with a record 936,000 starts in fiscal 2025. Strategic investments in AI-driven treatment planning and integrated digital workflows enhance clinical predictability and doctor efficiency.
Align is focused on operational efficiencies and expects a 100 basis point improvement in non-GAAP operating margin for fiscal 2026, reaching approximately 23.7%. This improvement is driven by product mix shifts towards more profitable lower-stage products and productivity gains, despite initial margin dilution from direct fabrication.
Bear case
The North American retail orthodontic market continues to experience softness due to pressured consumer sentiment and patient inflow, aligning with the broader 'White Collar Services' theme of reduced discretionary spending. This regional weakness offsets some of the international and DSO strength, creating an ongoing drag on overall performance.
Align faces persistent pressure on its clear aligner average selling prices (ASPs), which were down year-over-year in Q4 2025 and are projected to decline 1-2% for fiscal 2026. This is primarily due to higher discounts and a mix shift towards lower-priced countries and products, impacting revenue per case.
While direct fabrication is a long-term strategic initiative, it is expected to be margin dilutive in its early rollout phases during 2026. Margin accretion is not anticipated until late 2027 or 2028, indicating near-term pressure on gross margins as the company scales this new manufacturing process.
Bull / Bear Case
- Bear Case
- Align Technology faces ongoing headwinds from softness in the North American retail orthodontic market, pressured by consumer sentiment and discretionary spending. This regional weakness is a significant drag on overall performance, offsetting international and DSO strength. Clear aligner average selling prices (ASPs) are under persistent pressure, declining year-over-year in Q4 2025 and projected to decrease 1-2% for fiscal 2026 due to higher discounts and a mix shift to lower-priced offerings. The strategic initiative of direct fabrication is expected to be margin dilutive in its early 2026 rollout, with accretion not anticipated until late 2027 or 2028, creating near-term margin pressure. The macroeconomic environment remains dynamic, contributing to management's cautiously optimistic outlook.
- Bull Case
- Align Technology demonstrates robust international expansion, with double-digit clear aligner volume growth across EMEA, Latin America, and APAC, and significant patient milestones. Dental Service Organizations (DSOs) are a powerful, high-growth channel, comprising 25% of the business and driving substantial adoption of Invisalign and iTero systems. The company's innovative product portfolio, including Invisalign First and the Palate Expander, is fueling strong growth in the lucrative teen and kids segment, with record starts in fiscal 2025. Align anticipates a 100 basis point improvement in non-GAAP operating margin for fiscal 2026, driven by operational efficiencies and a favorable product mix, despite initial direct fabrication dilution. Competitors' price increases could also provide a tailwind.
- More Compelling & Why
- Bear. Align's P/E ratio of approximately 45-50x (TTM) appears stretched given its projected 3-4% revenue growth for 2026 and persistent ASP pressure. The strongest argument for the bear case is the continued softness in the North American retail market and the projected 1-2% decline in clear aligner ASPs, indicating fundamental challenges to top-line growth and profitability not fully reflected in the current valuation. My view would flip if Align could demonstrate sustained positive ASP growth or a clear and consistent rebound in North American retail volumes.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Clear Aligner Average Selling Price (ASP) Trend | Clear Aligner ASP directly impacts revenue and gross margins. Management's guidance for a 1-2% decline in 2026 ASPs, driven by higher discounts and mix shift to lower-priced products/countries, indicates ongoing pricing pressure and potential margin erosion. | Reported clear aligner average per case shipment price (ASP) for Q1 2026 and subsequent quarters, compared to prior periods and the guided 1-2% year-over-year decline for 2026. | Bearish if Q1 2026 ASP declines more than sequentially or year-over-year, or if the full-year 2026 ASP decline exceeds the 1-2% guidance. | Company earnings reports and conference calls (e.g., Q1 2026 earnings call expected in late April/early May 2026). | Industry reports on dental pricing trends (e.g., ADA surveys, market research firms). | Consumer transaction data (e.g., credit card data) for dental services, analyzing average spend per visit. |
| North America Retail Clear Aligner Volume Growth | North America retail is experiencing softness due to pressured consumer sentiment and patient inflow, aligning with the short thesis on discretionary spending. Continued weakness or further decline would confirm the bearish outlook for Align Technology. | Year-over-year percentage change in North America clear aligner volumes, specifically for the non-DSO (retail) segment, as reported in quarterly earnings. | Bearish if North America retail clear aligner volumes continue to decline year-over-year or show worsening sequential trends. | Company earnings reports and conference calls (e.g., Q1 2026 earnings call expected in late April/early May 2026). | Google Trends: 'Invisalign cost North America', 'orthodontist near me' search volume trends. | SimilarWeb: Align Technology website traffic (North America); Thinknum: Job postings for dental hygienists/assistants in private practices (North America). |
| Direct Fabrication Margin Impact | Direct fabrication is a new technology that management explicitly stated will be 'margin dilutive' in its early 2026 rollout, with accretion not expected until late 2027/2028. This directly impacts near-term profitability. | Management commentary on the magnitude of margin dilution from direct fabrication in Q1 2026 and subsequent quarters, and any updates to the timeline for achieving margin accretion. | Bearish if the margin dilution from direct fabrication is greater than anticipated, or if the timeline for achieving margin accretion is pushed back beyond late 2027/2028. | Company earnings reports and conference calls (e.g., Q1 2026 earnings call expected in late April/early May 2026). | Industry news and articles on 3D printing in dentistry, Align Technology patent filings related to direct fabrication. | Supply chain intelligence platforms tracking raw material costs for 3D printing resins. |
| China Volume-Based Procurement (VBP) Implementation | China is a significant international market for Align. While VBP is currently delayed and focused on public hospitals, any broader or faster implementation could lead to pricing pressure and volume shifts, impacting Align's business, which is 85% private sector. Guidance *excludes* VBP impact, making it an unquantified risk. | Official announcements from the Chinese government regarding the scope, timing, and pricing mechanisms of the VBP process for orthodontic devices, and any commentary from Align on its potential impact. | Bearish if VBP implementation expands beyond public hospitals to the private sector, or if the pricing reductions are more severe than anticipated, leading to a negative impact on Align's China revenue or volume. | Chinese government health authority websites (e.g., National Healthcare Security Administration), industry news outlets covering China's healthcare policy, Align's earnings calls. | News aggregators for 'China VBP orthodontics', 'China medical device pricing policy'. | GlobalData: Healthcare policy tracking for China; S&P Global Market Intelligence: Regulatory updates for medical devices in China. |
| Achievement of 2026 Non-GAAP Operating Margin Target | Management guided for a 100 basis point improvement in non-GAAP operating margin for fiscal 2026 (to ~23.7%). Failure to achieve this target, especially given ASP pressure and direct fabrication dilution, would indicate broader operational inefficiencies or worsening market conditions, confirming bearish sentiment. | Reported non-GAAP operating margin for Q1 2026 and subsequent quarters, and any revisions to the full-year 2026 non-GAAP operating margin guidance. | Bearish if Q1 2026 non-GAAP operating margin is below the guided 19.5% (sequential decline expected), or if management revises the full-year 2026 non-GAAP operating margin guidance downwards from 23.7%. | Company earnings reports and conference calls (e.g., Q1 2026 earnings call expected in late April/early May 2026). | Financial news sites tracking analyst consensus estimates for ALGN's margins. | Bloomberg Terminal/Refinitiv Eikon: Consensus estimates and historical margin data. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Worldwide Revenues | This metric indicates the overall financial health and market demand for Align Technology's products. It reflects the success of their strategic initiatives, including international expansion and DSO partnerships, which are crucial for top-line growth. | 5.3% |
| Non-GAAP Operating Margin | This metric reflects Align Technology's profitability and operational efficiency. It is particularly important as the company manages new product introductions like direct fabrication (which can be dilutive initially) and focuses on productivity improvements to enhance margins. | 13.0% |
| Clear Aligner Volume | Clear Aligner Volume is a direct measure of patient adoption and market share in Align's core business. Its growth indicates the effectiveness of efforts to increase utilization among teens and adults, especially amid broader market softness in North America. | 7.7% |
Key QuestionsCan Align Technology's North America retail clear aligner volumes avoid further sequential or year-over-year declines, given ongoing consumer sentiment pressure
Can Align Technology's North America retail clear aligner volumes avoid further sequential or year-over-year declines, given ongoing consumer sentiment pressure and its impact on discretionary spending?
- Question 2
Will the initial margin-dilutive impact of direct fabrication in 2026 be greater than anticipated, hindering Align Technology's ability to achieve its full-year non-GAAP operating margin improvement target?
- Question 3
Can Align Technology mitigate the projected 1-2% year-over-year decline in clear aligner average selling prices (ASPs) for 2026, or will unfavorable geographic and product mix, coupled with higher discounts, lead to a more significant ASP erosion?
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Expanding international adoption: Management highlighted strong performance in EMEA, Latin America, and APAC, and tailoring regional strategies to unlock demand. 2. Increasing orthodontic utilization, particularly among teens and kids: Emphasized growth in this category driven by products like Invisalign First, the Palate Expander, and MAOB. 3. Accelerating GP engagement and strengthening consumer demand conversion: Focused on leveraging DSOs, helping retail doctors adopt digital business methods, utilizing localized marketing, patient financing, and integrating iTero and Exocad into restorative and orthodontic workflows. | The call conveyed a cautiously optimistic tone. Management was pleased with the better-than-expected Q4 2025 results, which included record revenues and clear aligner volumes, and improved non-GAAP operating margin. Key takeaways included strong performance in international markets and with DSO partners, continued focus on the teen and growing kids segment, and strategic investments in innovation like AI-driven treatment planning and direct fabrication. Despite a dynamic macro environment, management expressed confidence in disciplined execution of their core strategic priorities to drive growth and value in 2026. | Clear Aligner revenues (Q3 2025): up 2.4% year-over-year. Imaging Systems and CAD/CAM Services (Systems and Services) revenues (Q3 2025): down 0.6% year-over-year. | 1. Improved volume performance and market trends vs. sales/marketing strategy: Analysts questioned if the improved volume was market-driven or due to Align's strategy. Management responded that it was primarily due to strong execution in DSOs, a robust product portfolio (Invisalign First, Palate Expander, MAOB), and active conversion approaches, with market trends described as stable. 2. Invisalign ASPs for 2026 and Q4 ASP performance: Analysts inquired about the expected 1-2% year-over-year ASP decline for 2026 and why Q4 ASPs were down sequentially. Management attributed the 2026 decline to country and product mix, and the Q4 sequential decline to unfavorable foreign exchange and strong growth in lower-priced countries. 3. Operating margin expansion and the impact of direct fabrication: Analysts pressed on the factors driving the 100 basis point margin improvement target for 2026 and the potential dilutive effect of direct fabrication. Management explained that margin improvement comes from product mix (lower-stage products being more profitable), productivity improvements, and volume leverage. They acknowledged direct fabrication would be margin dilutive in its early 2026 rollout but is included in the overall guidance, with accretion expected in late 2027/2028 as it scales. | Total revenues: up 5.3% year over year. Clear Aligner revenues: up 5.5% year over year. Imaging Systems and CAD/CAM Services (Systems and Services) revenues: up 4.2% year over year. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Align is expanding its eligible market by focusing on teens and growing kids, with a record 936,000 started treatment in FY25, up 7.8% year over year. The Invisalign First and Palate Expander System for ages 6-10 are strong drivers of early intervention adoption globally. International markets, particularly Latin America, EMEA, and APAC, are showing strong double-digit growth and reaching patient milestones (e.g., 1M patients in Latin America, UK, and Iberia). The company is also expanding access through a broader product portfolio with lower upfront cost options and strengthening capabilities across diagnostic, restorative, and orthodontic workflows to increase relevance in everyday oral healthcare for GPs and labs. DSOs, which represent about 25% of the business, are a key strategic growth channel, outpacing traditional retail practices and driving digital dentistry adoption. | Align asserts its leadership as the 'world's most sophisticated treatment planning and 3D printing manufacturing operation,' with unmatched ability to scale for rapidly growing DSOs compared to competitive suppliers. The company notes that many competitors are increasing their pricing 'for various reasons, in terms of tariffs or maybe it's profitability or other reasons,' which is seen as a 'good thing in the long run' and 'certainly helps us' going forward, though not factored into current guidance. | The dental industry is experiencing a significant trend of practice consolidation, with Dental Service Organizations (DSOs) and Orthodontic Service Organizations (OSOs) outpacing traditional retail practices globally. DSOs are becoming influential forces shaping digital dentistry, prioritizing efficiency, clinical predictability, improved patient experience, and scale, which aligns with Align's digital platform. There is broader orthodontic market softness in North America retail due to pressured consumer sentiment and patient inflow. Affordability remains a priority for patients, leading to increased partnerships with healthcare financing platforms like HFD. China's volume-based procurement (VBP) process continues to face implementation delays, with initial phases expected within the public hospital system before broader expansion; over 85% of Align's business in China is in the private sector. | Align expects Q1 2026 worldwide revenues to be in the range of $1.01B to $1.03B, up 3-5% year over year, with clear aligner volume up mid-single digits and ASP up sequentially from favorable geographic mix. For fiscal 2026, worldwide revenue growth is projected at 3-4% year over year, with clear aligner volume growth up mid-single digits. Non-GAAP operating margin is expected to be approximately 23.7%, a 100 basis point improvement year over year. The company plans capital expenditures of $125M-$150M for technology upgrades, additional manufacturing capacity, and maintenance. Align is on track for limited market release of Invisalign First Direct 3D printed retainers and Invisalign Specifics 3D printed prefab attachments in 2026, with more complex products in 2027. Direct fabrication is expected to be margin dilutive initially but move to margin accretion in late 2027/2028. Broader rollout of Exocad ART (advanced restorative treatment) is planned for 2026. | The | Practice consolidation in dentistry through DSOs and OSOs, driving a shift towards digital dentistry. Increasing importance of patient affordability and financing solutions in healthcare. Government intervention in healthcare pricing, as seen with China's VBP process. Continued macroeconomic uncertainty impacting consumer sentiment and discretionary spending. | Q4 revenues were a record $1,048,000,000, up 5.3% year over year and 5.2% sequentially. For the full year 2025, total revenues were a record $4,000,000,000. Fiscal 2025 clear aligner revenues were $3,200,000,000, up 0.5% year over year on record clear aligner volumes of 2,600,000 cases, which are up 4.7% year over year. For the year, a record 936,000 teens and kids started treatment with Invisalign clear aligners, up 7.8% year over year for fiscal 2025. We also delivered fiscal 2025 non-GAAP operating margin of 22.7%, above our 2025 outlook. Over 296,000 active Invisalign-trained doctors have treated over 22 million people worldwide. North America DSO Performance Remained Very Strong. Delivering Double Digit Year Over Year Growth Led By Strength In The Adult Category. In EMEA, clear aligner volumes grew double digits. Year over year reaching record Q4 levels. In APAC, clear aligner volumes grew double digits year over year. Lumina represented approximately 86% of full systems units in the quarter. Q4 was a good finish to the year. With results that came in better than expected and reflect the continued strength of our business fundamentals. | broader orthodontic market softness in North America retail chain where consumer sentiment and patient inflow remained pressured. Sequentially, case starts declined 9.8% as expected, following an exceptionally strong Q3 teen season. direct fabrication will unlock new design flexibility, and, over time, reduce waste and lower cost although early production has some dilutive margin impact until scale. Q4 clear aligner average per case shipment price was $1,240 down $25 on a year over year basis, primarily due to higher discounts mix shift to lower price countries and products. Q1 twenty twenty six GAAP operating margin to be 12.4% to 12.8%, down sequentially. While the macro environment remains dynamic, we are cautiously cautiously optimistic. I wouldn't call the economic situation in The United States better in any way in a sense of driving volume in that way. expect ASPs to work, you know, kind of model maybe one to 2% down. Overall. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-04 | Align Technology reported better-than-expected Q4 2025 results, achieving record revenues and clear aligner volumes, alongside its highest non-GAAP operating margin since 2021. Key drivers included strong international growth, robust DSO partnerships, and increased teen/kid adoption. The company issued an optimistic 2026 outlook, projecting 3-4% revenue growth and 100 bps operating margin expansion. The market reacted very positively, with the stock significantly outperforming SPY, indicating strong confidence in ALGN's performance and strategic direction. | Earnings Transcript | Neutral | False | +16.31% (vs SPY: +15.18%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| ALGN_3f7f8f5e | early phases are expected to begin within the public hospital system before expanding more broadly | 2026-01-01 | 2026-12-31 | Implementation of China's Volume-Based Procurement (VBP) process for clear aligners, starting with public hospitals and potentially expanding. | VBP could lead to pricing changes and impact clear aligner volumes in China. While Align believes it is well-positioned, the timing and scope remain fluid, and current guidance does not include any VBP impact, so materialization could affect results. | Ticker | 2026-02-04 | earnings_transcript |
| ALGN_e1f92ae6 | in 2026 | 2026-01-01 | 2026-12-31 | Limited market release of Invisalign First Direct 3D printed retainers and Invisalign Specifics 3D printed prefab attachments. | This product ramp represents a shift to direct fabrication, which is expected to be margin dilutive in early production but will reduce waste and lower costs, enhancing margins over time as it scales. | Ticker | 2026-02-04 | earnings_transcript |
| ALGN_46d98161 | this year | 2026-01-01 | 2026-12-31 | Broader rollout of Exocad ART (Advanced Restorative Treatment) software. | This product expansion is expected to increase software-driven recurring revenue and enhance efficiency for doctors and labs, supporting broader digital adoption and creating more opportunities for iTero scanning and Invisalign treatment. | Ticker | 2026-02-04 | earnings_transcript |
| ALGN_269e93a8 | Continues to roll out in in in Q1. And like Joe said, it'd be mostly full fully rolled out into q into '26. | 2026-01-01 | 2026-12-31 | Broader rollout of 'no AA' (no additional aligners) product configurations. | These products offer more flexibility and lower upfront costs for doctors, potentially driving adoption and increasing revenue recognition upfront as there is no deferred revenue on a no-refinement product. | Ticker | 2026-02-04 | earnings_transcript |